China’s Losartan Potassium market remained firm during the first half of May 2026, supported by strong export demand, rising production expenses, and elevated freight costs. Chinese exporters maintained firm offers as higher crude oil and natural gas prices increased manufacturing costs, while disruptions around the Strait of Hormuz pushed shipping and logistics expenses higher. Sustained export enquiries and tightening spot availability further reinforced bullish sentiment in the Losartan Potassium market. The strong market conditions in May followed the upward momentum observed throughout April, when overseas demand from the United States and Brazil absorbed a significant share of Chinese Losartan Potassium output. Export-oriented pharmaceutical manufacturers and generic-drug producers increased procurement activity ahead of third-quarter formulation runs, while domestic hospital purchasing remained comparatively subdued due to procurement controls under China’s Volume-Based Procurement framework. Supply-side pressures also contributed to the firm market environment, as producers faced rising costs for potassium hydroxide, aromatic nitrile intermediates, and specialty solvents. Looking ahead, the Losartan Potassium market is expected to witness further modest gains in the second half of May if export demand and feedstock cost pressures continue to persist.
